“I used the xCELLigence DP system to study the effectiveness of CAR-T against target cancer cells. I was able to observe the effectiveness of cell therapy during the entire experiment with great accuracy. Both devices and software are easy and pleasant to use”

"xCELLigence system is helping my research with fast and reliable screening experiments on cells proliferation, migration and invasion under different cells growth conditions."

"We purchased the system as we had a good experience with it in past – our group works in the field of nanomedicine. In experiments, various nanomaterials (carbon, magnetic particles) are modified by antitumor drugs and other molecules for specific targeting of tumor cells.
The the greatest benefit of the system is that the experiments are easy to set up, the data are obtained in a relatively short time without the need for more complicated sample manipulation. The method makes it possible not only to monitor the increasing number of cells, but also to evaluate the progress of this process - to elegantly determine the growth characteristics of the studied cells and to test the substances used. The process is completely independent of the human factor, thereby minimizing common experimental errors."

The xCELLigence RTCA DP system is an easy to use platform with intuitive software and a variety of online tutorials for beginners and experience users. It is great tool for our cell therapies development, our laboratory obtained exciting results for cytotoxicity assays using adherent and suspension cells.

"The xCELLigence RTCA SP analysis is without any doubts a proven non-invasive and sensitive method for monitoring the viability, proliferation or migration of cells in real time and thus complements and explains a number of end-point experiments. Our laboratory deals with the study of new natural molecules or compounds prepared semisynthetically. The analysis software is also intuitive and complete, moreover, ACCELA as a local supplier is able to provide qualified training and service."